Basics Celldex Therapeutics, Inc. Celldex Therapeutics Inc is a biopharmaceutical company. The company is engaged in the development and commercialization of immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. IPO Date: March 26, 1990 Sector: Healthcare Industry: Biotech Market Cap: $1.33B Activated in VL: True Average Daily Range Avg Daily Range: $0.43 | 3.07% Avg Daily Range (30 D): $0.51 | 2.58% Avg Daily Range (90 D): $0.59 | 3.00% Institutional Daily Volume Avg Daily Volume: 1.1M Avg Daily Volume (30 D): .7M Avg Daily Volume (90 D): .65M Trade Size Avg Trade Size (Sh.): 164 Avg Trade Size (Sh.) (30 D): 63 Avg Trade Size (Sh.) (90 D): 62 Institutional Trades Total Inst.Trades: 4,368 Avg Inst. Trade: $2.08M Avg Inst. Trade (30 D): $2.84M Avg Inst. Trade (90 D): $2.47M Avg Inst. Trade Volume: .05M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $2.85M Avg Closing Trade (30 D): $2.39M Avg Closing Trade (90 D): $2.74M Avg Closing Volume: 74.21K     News Mar 3, 2025 @ 1:01 PM Celldex Therapeutics Presents Positive Preclinical... Source: N/A Mar 1, 2025 @ 5:45 PM Celldex Therapeutics Presents Positive Results fro... Source: N/A Feb 20, 2025 @ 6:00 PM Chronic Spontaneous Urticaria Market to Register I... Source: Delveinsight Dec 19, 2024 @ 1:01 PM Celldex Initiates Phase 2 Study of Barzolvolimab i... Source: N/A Nov 4, 2024 @ 6:00 PM Urticaria Clinical Trial Pipeline Accelerates: 20+... Source: Delveinsight Financials   TTM Q4 2024 FY 2024 Basic EPS $-.81 $-.71 $-2.45 Diluted EPS $-.81 $-.71 $-2.45 Revenue $ .7M $ 1.18M $ 7.02M Gross Profit $ $ $ 6.82M Net Income / Loss $ -53.8M $ -47.09M $ -157.86M Operating Income / Loss $ -62.74M $ -56.03M $ -195.08M Cost of Revenue $ $ $ .2M Net Cash Flow $ -11.22M $ -8.04M $ -6.46M PE Ratio     Splits Feb 11, 2019:   1:15 Mar 10, 2008:   1:12 Mar 07, 2008:   1:12